» Articles » PMID: 20388916

Identification of the MiR-106b~25 MicroRNA Cluster As a Proto-oncogenic PTEN-targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation

Abstract

PTEN (phosphatase and tensin homolog deleted on chromosome 10) is a tumor suppressor that antagonizes signaling through the phosphatidylinositol 3-kinase-Akt pathway. We have demonstrated that subtle decreases in PTEN abundance can have critical consequences for tumorigenesis. Here, we used a computational approach to identify miR-22, miR-25, and miR-302 as three PTEN-targeting microRNA (miRNA) families found within nine genomic loci. We showed that miR-22 and the miR-106b~25 cluster are aberrantly overexpressed in human prostate cancer, correlate with abundance of the miRNA processing enzyme DICER, and potentiate cellular transformation both in vitro and in vivo. We demonstrated that the intronic miR-106b~25 cluster cooperates with its host gene MCM7 in cellular transformation both in vitro and in vivo, so that the concomitant overexpression of MCM7 and the miRNA cluster triggers prostatic intraepithelial neoplasia in transgenic mice. Therefore, the MCM7 gene locus delivers two simultaneous oncogenic insults when amplified or overexpressed in human cancer. Thus, we have uncovered a proto-oncogenic miRNA-dependent network for PTEN regulation and defined the MCM7 locus as a critical factor in initiating prostate tumorigenesis.

Citing Articles

A systematic review of mechanisms of PTEN gene down-regulation mediated by miRNA in prostate cancer.

Bergez-Hernandez F, Irigoyen-Arredondo M, Martinez-Camberos A Heliyon. 2024; 10(15):e34950.

PMID: 39144981 PMC: 11320309. DOI: 10.1016/j.heliyon.2024.e34950.


Coding, or non-coding, that is the question.

Poliseno L, Lanza M, Pandolfi P Cell Res. 2024; 34(9):609-629.

PMID: 39054345 PMC: 11369213. DOI: 10.1038/s41422-024-00975-8.


PIAS family in cancer: from basic mechanisms to clinical applications.

Li X, Rasul A, Sharif F, Hassan M Front Oncol. 2024; 14:1376633.

PMID: 38590645 PMC: 10999569. DOI: 10.3389/fonc.2024.1376633.


Current evidence regarding the cellular mechanisms associated with cancer progression due to cardiovascular diseases.

Attachaipanich T, Chattipakorn S, Chattipakorn N J Transl Med. 2024; 22(1):105.

PMID: 38279150 PMC: 10811855. DOI: 10.1186/s12967-023-04803-2.


MicroRNAs as Potential Biomarkers of Environmental Exposure to Polycyclic Aromatic Hydrocarbons and Their Link with Inflammation and Lung Cancer.

Letelier P, Saldias R, Loren P, Riquelme I, Guzman N Int J Mol Sci. 2023; 24(23).

PMID: 38069307 PMC: 10707120. DOI: 10.3390/ijms242316984.


References
1.
Ambs S, Prueitt R, Yi M, Hudson R, Howe T, Petrocca F . Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008; 68(15):6162-70. PMC: 2597340. DOI: 10.1158/0008-5472.CAN-08-0144. View

2.
Voorhoeve P, le Sage C, Schrier M, Gillis A, Stoop H, Nagel R . A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006; 124(6):1169-81. DOI: 10.1016/j.cell.2006.02.037. View

3.
Grimson A, Farh K, Johnston W, Garrett-Engele P, Lim L, Bartel D . MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007; 27(1):91-105. PMC: 3800283. DOI: 10.1016/j.molcel.2007.06.017. View

4.
Xiao C, Srinivasan L, Calado D, Patterson H, Zhang B, Wang J . Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008; 9(4):405-14. PMC: 2533767. DOI: 10.1038/ni1575. View

5.
Ren B, Yu G, Tseng G, Cieply K, Gavel T, Nelson J . MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene. 2005; 25(7):1090-8. DOI: 10.1038/sj.onc.1209134. View